Quantcast

Europe

Sanofi appoints new EVP Diabetes & Cardiovascular

Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effectively immediately.

Posted in Europe, news, Regions | Tagged , , | Leave a comment

Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress

Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.

Posted in Europe, news, Regions | Tagged , , , | Leave a comment

Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”

Posted in Europe, news, North America, studies | Tagged , , , , | Leave a comment

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.

Posted in Europe, news, Regions | Tagged , , , , , | Leave a comment

Allergy Therapeutics wins approval for PQ Grass phase II trial

Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.

Posted in Europe, news, Regions | Tagged , , | Leave a comment

Novartis’s adalimumab offers alternative for patients with immunological diseases

Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.

Posted in Europe, news, Regions | Tagged , | Leave a comment

Cardiome Pharmato to sell Basilea Pharmaceutica’s antibiotic in Nordic Europe and Israel

Basilea Pharmaceutica’s Basilea Pharmaceutica International Ltd. has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea’s antibiotic Zevtera/Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and Israel.

Posted in Europe, news, Regions | Tagged , , | Leave a comment

Sandoz proposed biosimilar rituximab accepted for review by the FDA

Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

Posted in Approval, Europe, news, North America, Regions | Tagged , , , | Leave a comment

Novartis’s new drug reduces cardiovascular risk

Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.

Posted in Europe, news, Regions | Tagged , , | Leave a comment

Karo Pharma to buy Weifa for €138M

Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.

Posted in Europe, news, Regions | Tagged , | Leave a comment